INTRODUCTION AND OBJECTIVES:
The objective of this study is to evaluate the outcomes of bladder augmentation in the adult population in a multicenter study. A secondary objective is to compare outcomes between patients who underwent a concomitant catheterizable channel placement vs. those who underwent a bladder augmentation alone.
METHODS: We reviewed the charts of 193 patients from 7 sites from the Neurogenic Bladder Research Group who underwent bladder augmentation between July 2007 and September 2017. 23 patients were excluded due to age under 18 (2) or follow-up < 6 months (21). We evaluated patient demographics, modality and type of surgery, 90-day complications and readmissions, and follow-up surgeries.
RESULTS: A total of 170 patients with a median age of 37 years were included in the study. 73 (43%) patients were male and the leading etiologies were spinal cord injury (81, 47%) and spina bifida (25, 15%). Prior to surgery, most patients' bladder management was clean intermittent catheterization (76, 45%), followed by indwelling urethral catheter or suprapubic tube (61, 36%). 137 (81%) patients underwent a bladder augmentation with a catheterizable channel, while 33 (19%) patients underwent a small bowel augmentation alone. The median length of hospital stay was 8 days (IQR 7-11) for channel patients and 7 days (IQR 6-10) for augment-only patients. The 90-day major complication rate was 13% (22 patients), which included 17 (12%) channel patients and 5 (15%) augment-only patients (p [ 0.40). In the 90-day post-operative period, 33 (19%) patients were readmitted and there were 0 deaths; there were no statistically significant differences between the two groups. Beyond the 90-day period, 64 patients (38%) underwent a total of 90 surgeries related to their bladder augment. 6 of the 33 (18%) augment-only patients underwent 9 surgeries while 58 of the 137 (42%) channel patients underwent 81 surgeries (p [ 0.01), 36 of which were for channel-specific complications (i.e. stenosis, leakage, and parastomal hernia).
CONCLUSIONS: This is the first contemporary multicenter series evaluating bladder augmentation in the adult population. 90-day major complication rates were low, but many of these patients-primarily the ones with catheterizable channels-required follow-up surgeries.
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MP07-09 INTRADETRUSOR ONABOTULINUMTOXINA FOR NON-CATHETERIZING MALES WITH NEUROGENIC DETRUSOR OVERACTIVITY
Alexandra Berger*, Cambridge, MA; Valary Raup, Graeme Steele, Elodi Dielubanza, Boston, MA INTRODUCTION AND OBJECTIVES: Intradetrusor OnabotulinumtoxinA (BTX-A) is an effective therapy for neurogenic detrusor overactivity (NDO). However, it may be underutilized in noncatheterizing male patients with NDO due to concern for urinary retention, as published rates of retention vary widely and have been established using cohorts which are majority female. We sought to describe the use and outcomes of BTX-A injections in real world cohort of non-catheterizing men with NDO.
METHODS: We utilized the Research Patient Data Registry to identify male patients with NDO who underwent BTX-A injections at our institution between 2006-2018. Demographic and clinical data were recorded. Descriptive statistics, chi squared, and Wilcoxon rank sum tests were used for analysis.
RESULTS: We identified 71 non-catheterizing men with NDO who underwent BTX-A, 38 (53.5%) with MS, 28 (39.4%) with PD, and 5 (7.0%) with another neurologic condition. Baseline AUA symptom scores were similar across groups. MS patients were significantly younger than all others. Pre-operative post-void residual urine volume (PVR) was available 63 patients (88.7%) with a median of 55mL (0-406). Patients with MS had higher baseline PVR than those with PD or other neurologic diagnosis (144.5 vs. 37 vs. 0, p[0.0018) . The 100 unit dose was utilized in 52% and 200 unit dose in 42%, with no difference in dose distribution across groups. After BTX-A, the median PVR was significantly higher 200mL (p[0.0052). Urinary retention requiring catheterization occurred in 20 (28.2%), with 11 (15.5%) patients requiring long-term catheterization. Repeat BTX-A was performed in 29 patients (40.8%) at a median of 366 (range 70-2785) days after initial treatment. The mean number of BTX-A treatments was 1.99 (1-10). Patients who required catheterization after BTX-A were less likely to have repeat injections (50.0% vs 20.0%, p[0.019). Neither dose nor disease type impacted urinary retention or repeat treatment.
CONCLUSIONS: In our series, intradetrusor BTX-A in noncatheterizing men with neurogenic detrusor activity was associated with at least transient urinary retention in <1/3rd of patients. Urinary retention was a predictor of treatment discontinuation. This therapy deserves further study in male populations.
